重新调整用途
生物医学
大数据
药物重新定位
数据科学
计算机科学
临床试验
药物发现
医疗保健
药物开发
人工智能
医学
药品
生物信息学
工程类
药理学
病理
数据挖掘
生物
经济
废物管理
经济增长
作者
Michel Lopes Leite,Lorena Sousa de Loiola Costa,Victor Albuquerque Cunha,Victor Kreniski,Mário de Oliveira Braga Filho,Nicolau Brito da Cunha,Fabrício F. Costa
标识
DOI:10.1016/j.drudis.2021.07.002
摘要
• Recently, the amount of health and “omics” data generated and stored has grown. • AI has been used for years by technology companies such as Apple, Amazon, Google and others. • AI is catching up with the life sciences’ sector and big pharma, mainly biomedicine and healthcare. • AI is improving patient and clinical trials’ data collection for drug development and repurposing. • Mobile technologies associated to AI have also been used to improve patient’s lives. Over the past few decades, the number of health and ‘omics-related data’ generated and stored has grown exponentially. Patient information can be collected in real time and explored using various artificial intelligence (AI) tools in clinical trials; mobile devices can also be used to improve aspects of both the diagnosis and treatment of diseases. In addition, AI can be used in the development of new drugs or for drug repurposing, in faster diagnosis and more efficient treatment for various diseases, as well as to identify data-driven hypotheses for scientists. In this review, we discuss how AI is starting to revolutionize the life sciences sector.
科研通智能强力驱动
Strongly Powered by AbleSci AI